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Effective vaccination against rabies in puppies
in rabies endemic regions
M. K. Morters, S. McNabb, D. L. Horton, A. R. Fooks, J. P. Schoeman, H. R. Whay, J. L. N. Wood,
S. Cleaveland
In rabies endemic regions, a proportionally higher incidence of rabies is often reported in
dogs younger than 12 months of age, which includes puppies less than 3 months of age; this
presents a serious risk to public health. The higher incidence of rabies in young dogs may be
the effect of low vaccination coverage in this age class, partly as a result of the perception
that immature immune systems and maternal antibodies inhibit seroconversion to rabies
vaccine in puppies less than three months of age. Therefore, to test this perception, the
authors report the virus neutralising antibody titres from 27 dogs that were vaccinated with
high quality, inactivated rabies vaccine aged three months of age and under as part of larger
serological studies undertaken in Gauteng Province, South Africa, and the Serengeti District,
Tanzania. All of these dogs seroconverted to a single dose of vaccine with no adverse
reactions reported and with postvaccinal peak titres ranging from 2.0 IU/ml to 90.5 IU/ml.
In light of these results, and the risk of human beings contracting rabies from close contact
with puppies, the authors recommend that all dogs in rabies endemic regions, including
those less than three months of age, are vaccinated with high quality, inactivated vaccine.
Introduction
Canine-mediated human rabies kills approximately 60,000
people every year (WHO 2013, Hampson and others 2015).
Mortality from rabies is highest in less developed communities
in Asia and Africa where domestic dogs are free-roaming
(Ezeokoli and Umoh 1987, Butler and Bingham 2000, Kitala and
others 2002, Kayali and others 2003, Windiyaningsih and others
2004, Reece and Chawla 2006, Kasempimolporn and others
2008, WHO 2013); with increasing evidence that the majority
are owned (Ezeokoli and Umoh 1987, Butler and Bingham 2000,
Estrada and others 2001, Windiyaningsih and others 2004, van
Sittert and others 2010, Gsell and others 2012, Morters and
others 2014b) and, thus, generally accessible for vaccination
(Lembo and others 2010, Knobel and others 2013).
Mass vaccination of domestic dogs is key to the successful
control of canine rabies, and a strong body of theoretical and
empirical evidence indicates that vaccinating 70 per cent of the
dog population during annual campaigns should be sufﬁcient to
control rabies (Coleman and Dye 1996, Cleaveland and others
2003, 2006, Belotto and others 2005, Schneider and others 2005,
Hampson and others 2009, WHO 2013). Achieving vaccination
coverage of 70 per cent during campaigns should maintain popu-
lation immunity above the critical levels of 20–45 per cent
required to interrupt rabies transmission (Coleman and Dye
1996, Hampson and others 2009). Effective coverage has been
achieved through vaccinating juveniles and adults (Chomel and
others 1987, Beran 1991, de Balogh and others 1993,
Mitmoonpitak and others 1998, Matter and others 2000,
Flores-Ibarra and Estrella-Valenzuela 2004, Touihri and others
2011), given that puppies less than three months of age are often
excluded from vaccination programmes (Chomel and others
1987, Beran and Frith 1988, Brooks 1990, Matter and Fico 1998,
Mitmoonpitak and others 1998, Matter and others 2000,
Gunatilake and others 2003, Flores-Ibarra and Estrella-Valenzuela
2004, Awoyomi and others 2007, Durr and others 2009, Touihri
and others 2011).
Low vaccination coverage in puppies has important implica-
tions for public health, especially as vaccination coverage of the
population and, thus, herd immunity declines following a vac-
cination campaign. A proportionally higher incidence of rabies is
often reported in dogs under 12 months of age, which includes
puppies less than three months of age (Belcher and others 1976,
Malaga and others 1979, Beran 1991, Mitmoonpitak and others
1998, Widdowson and others 2002). In these studies, the propor-
tion of laboratory conﬁrmed cases in dogs under three months of
age range from 7.6 per cent to 17.4 per cent. This presents a
serious risk to the public, given that the fraction of puppies less
than three months of age in a population may be large, report-
edly ranging from 4.1 per cent to 39 per cent (Davlin and
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VonVille 2012), and the close relationship between human
beings and puppies (Mitmoonpitak and others 1997, Taiwo and
others 1998, WHO 1998, Widdowson and others 2002,
Awoyomi and others 2007).
Puppies less than three months of age are generally excluded
from rabies vaccination programmes on the assumption that
they have immature immune systems and maternal antibodies
(Day 2007, Siegrist 2008, Hodgins and Shewen 2012) which may
limit the immune response to rabies vaccine. Primarily to safe-
guard against possible inhibitory effects of maternal antibody,
most manufacturers of high quality, inactivated rabies vaccines
for dogs recommend a primary or booster vaccination at 12–13
weeks (Merial Animal Health Limited, MSD Animal Health).
Similarly, internationally recognised vaccination guidelines for
dogs recommend primary vaccination against rabies at 12–13
weeks of age (WSAVA 2010, AAHA 2011). Consequently, those
administering vaccine under ﬁeld conditions may be reluctant to
use rabies vaccines off-label (Awoyomi and others 2007, Touihri
and others 2011); even though World Health Organization
(WHO) guidelines recommend that all dogs, including puppies
less than three months of age, are vaccinated during mass vaccin-
ation campaigns (WHO 2004, 2013) when booster vaccinations
are generally not available. Furthermore, owners also often per-
ceive puppies as too young for vaccination (Flores-Ibarra and
Estrella-Valenzuela 2004, Kongkaew and others 2004, Kaare and
others 2009, Davlin and others 2013) so they are often not pre-
sented for vaccination during campaigns.
Evaluation of the effect of maternal antibodies and immune
function of puppies on rabies vaccine induced immune responses
is limited. Maternal antibody may interfere with immune
responses (Day and Schultz 2011, Siegrist 2012, Tizard 2013),
particularly in puppies eight weeks of age or younger vaccinated
with modiﬁed live rabies vaccine under ﬁeld conditions (Aghomo
and others 1990). However, at least under experimental condi-
tions, maternal antibodies and immune function may not limit
the immune response to inactivated vaccines which stimulate
both B cell and T cell responses (Siegrist 2012), as demonstrated
in puppies vaccinated with Rabisin® (Merial Animal Health
Limited) at two weeks of age (Chappius 1998). The authors
present serological data from puppies vaccinated under ﬁeld con-
ditions in South Africa and Tanzania that support these prior
observations.
Materials and methods
Puppies (hereafter deﬁned as dogs three months of age and
under) were vaccinated as part of larger serological studies in ﬁve
low-income communities of Africa where the dogs are owned,
with the majority being mixed-breed and free to roam. The ﬁve
communities include the township of Zenzele in Gauteng
Province, South Africa (Morters and others 2014a, b), and four
villages (Ngarawani, Rung’abure, Nyamburi and Bisarara, here-
after referred to as ‘Serengeti’) in the Serengeti District, Tanzania
(McNabb 2008). Vaccinations for this study were undertaken
during February 2010 in Zenzele and May 2008 in the Serengeti.
None of the puppies were vaccinated prior to this study. Central
point vaccination campaigns had also been undertaken in
Zenzele by the Department of Agriculture (DoA) in May 2006.
In the Serengeti, annual central point vaccinations have been
undertaken since 2003 as part of studies to investigate and
prevent canid diseases (Kaare and others 2009).
For the puppies in the Serengeti and those acquired from
outside of Zenzele, age was reported by the owner but validated
by direct observation and tooth eruption (Dyce and others
1987). For puppies born in Zenzele, age was determined from
intensive monitoring of the dams generating reliable whelping
dates, direct observation and tooth eruption (Morters and others
2014b).
In Zenzele, every available dog (n=259) in the entire popula-
tion (of 315), including 68 puppies (from a total of 86 in the
population) and their dams, were vaccinated door-to-door with
1 ml of Rabisin® (Merial Animal Health Limited), an inactivated
rabies vaccine containing at least 1 International Unit (IU) of
rabies virus glycoprotein GS57 Wistar strain. Vaccine was admi-
nistered subcutaneously into the nape of the neck.
In the Serengeti, eight puppies in a convenience sample of
200 dogs brought to a central vaccination station were vacci-
nated with 1 ml of Nobivac® Rabies (MSD Animal Health) sub-
cutaneously into the nape of the neck. Nobivac® Rabies
contains >2 IU inactivated Rabies Virus strain Pasteur RIV. Ten
ml of Nobivac® Rabies was used to reconstitute one vial of
Nobivac® Puppy DP (containing live attenuated CPV strain C
154 and CDV strain Onderstepoort) (MSD Animal Health), thus
the puppies were simultaneously vaccinated against Canine
Parvo Virus (CPV) and Canine Distemper Virus (CDV). In add-
ition, 0.01 ml/kg of ivermectin (Ivomec) was administered to a
proportion of the puppies. In both locations the vaccine cold
chain was carefully maintained.
The majority of the (68) puppies in Zenzele were <6–8
weeks of age when vaccinated and deemed too small to blood
sample immediately prior to vaccination without causing
unnecessary distress to the puppy and/or owner (see online sup-
plementary Table S1 for the age distribution at vaccination of
the (68) puppies). Therefore, prevaccinal virus neutralising anti-
body titres (hereafter referred to as ‘titres’) were obtained from
only four of the puppies. To measure postvaccinal peak titres
blood samples were collected approximately 30 days following
vaccination. Thirty-seven of the 68 vaccinated puppies remained
in Zenzele 30 days after vaccination, and of these 19 were big
enough to blood sample (see online supplementary Table S1 for
the outcomes of the (68) vaccinated puppies). In the Serengeti,
blood samples were collected from all eight puppies immediately
prior to vaccination and 21 days later. All samples were centri-
fuged within eight hours of collection, and the sera were either
chilled or frozen from the time of collection until they were
shipped to the Animal and Plant Health Agency, UK, where
titres were measured by ﬂuorescent antibody virus neutralisation
(FAVN) test, a method prescribed by the Ofﬁce International des
Epizooties (OIE) (Cliquet and others 1998). Aliquots of the sera
were also transported chilled from the Serengeti to Cornell
University, USA, where titres for CDV and CPV were measured
by virus neutralisation and haemagglutination inhibition tests,
respectively.
All puppies were examined by a veterinarian at the time of
vaccination and blood sampling. In Zenzele, every owner was
made aware of the emergency phone number (written on their
dog’s vaccination certiﬁcate) to contact the veterinarian if any
abnormalities in the health or behaviour of their dog were
observed following vaccination. Every house in Zenzele in which
a puppy was vaccinated in February 2010 was revisited twice by
the veterinarian during March 2010 to collect (i) demographic
data by direct observation and owner questionnaire, and (ii) day
30 postvaccinal blood samples as part of larger dog demography
(Morters and others 2014b) and aforementioned serological
(Morters and others 2014a) studies, respectively. During each
visit, every available vaccinated puppy underwent a health
assessment irrespective of whether a blood sample was collected
or not. See online supplementary Table S1 for a description of
the health assessments of the (68) puppies vaccinated in Zenzele
in February 2010.
The study in South Africa was approved by the Ethics
Committee, University of Cambridge, and the Research and
Animal Ethics Committees, University of Pretoria, and the study
in Tanzania was approved by the Tanzanian Commission for
Science and Technology, Tanzania Wildlife Research Institute,
and the Royal (Dick) School of Veterinary Studies, Edinburgh. In
Tanzania the blood samples were collected during an ongoing
vaccination programme undertaken by the Serengeti Health
Initiative. In all cases, vaccination and blood sampling were only
carried out with the owner, or responsible adult delegated by the
owner, present and their informed consent.
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Results
In Zenzele, titres for the four puppies sampled immediately
prior to vaccination were ≤0.13 IU/ml, similar to prevaccinal
titres in 32 dogs 1.5–4.5 months of age from dams vaccinated
with high quality, inactivated vaccine against rabies in Thailand
(Kasempimolporn and others 1996, Tepsumethanon, personal
communication, 2015). Prevaccinal titres for the eight puppies in
the Serengeti were <0.3 IU/ml (ranging from 0.07 IU/ml to
0.29 IU/ml). Postvaccinal peak (i.e. day 30) titres for the (19)
puppies in Zenzele are shown in Table 1. All of the puppies sero-
converted to the vaccine (i.e. generated titres ≥0.5 IU/ml
(Kennedy 1998)), with a geometric mean titre of 20.7 IU/ml.
Seventeen of the 19 puppies (blood sampled on day 30) were
born in Zenzele to eight dams; all of the adult females were sero-
negative (<0.5 IU/ml) immediately prior to vaccination in
February 2010 (Table 1). Five of the dams were present in Zenzele
in May 2006 and may have been vaccinated by the DoA, however
none had a titre suggestive of an anamnestic response to vaccin-
ation (deﬁned as a peak titre ≥128 IU/ml (Morters and others
2014a)) in February 2010 (day 30 titres ranged from 0.09 IU/ml to
90.5 IU/ml). The other two puppies (blood sampled on day 30)
were obtained from outside Zenzele, therefore the vaccination
status of their dams was not known. Only 5 of the (68) vaccinated
puppies were still in Zenzele 90 days after vaccination, and of
these 4 remained 12 months after vaccination (with day 360 titres
of 0.09 IU/ml, 0.35 IU/ml, 0.35 IU/ml and 1 IU/ml). This includes
one puppy born in Zenzele that was not blood sampled 30 days
following vaccination; however titres for this puppy 90 days, 180
days and 360 days following vaccination were ≥0.5 IU/ml. The
dam of this puppy was vaccinated with Rabisin® in October 2009
with an anamnestic response to the vaccine (day 30 titre of
128 IU/ml), consistent with possible vaccination also in May
2006. See online supplementary Table S1 for the prevaccinal and
postvaccinal titres of the (68) puppies and their dams.
All (8) puppies in the Serengeti seroconverted to the rabies
vaccine at 21 days following vaccination, with all titres exceeding
5.9 IU/ml (Table 2). In this site, no data were available for end-
point titres, vaccination status of the dams or survival of the
puppies beyond the 21-day follow-up period. In the Serengeti,
where CDV and CPV were administered simultaneously with
Nobivac® Rabies, all (8) puppies also seroconverted to CDV and
CPV with high 21-day postvaccinal antibody titres of ≥256 and
≥640, respectively. See online supplementary Table S2 for the
prevaccinal and postvaccinal CDVand CPV titres.
At the time of blood sampling and the health assessment,
there were no reports or clinical signs of type IV hypersensitivity
reactions (i.e. granulomas or sterile abscesses at the injection
site), the main risk associated with the use of inactivated
vaccine with adjuvant (Merial Animal Health Limited, MSD
Animal Health, Tizard 2013). Although 14 puppies in Zenzele
died before the ﬁrst household visit in March 2010 (see online
supplementary Table S1), none were reported to have died the
day of vaccination, suggestive of a type I hypersensitivity (ana-
phylactoid) reaction which may occur up to two hours or three
hours following vaccination (Tizard 2013); nor were there any
reports of type IV hypersensitivity reactions.
Discussion
The present study shows that puppies from low-income com-
munities in rabies endemic regions respond well to a standard
dose of high quality, inactivated rabies vaccine without any
apparent adverse reactions (Merial Animal Health Limited, MSD
Animal Health, Tizard 2013). All the puppies sampled following
vaccination in this study generated antibody titres >0.5 IU/ml
after vaccination, and most individuals recorded much higher
titres. Although the sample was small, somewhat related to the
poor general background survival of puppies here (see online sup-
plementary Table S1), this result was consistent across the study
group irrespective of the levels of prevaccinal antibody, the
administration of ivermectin at the time of vaccination, or con-
current vaccination against CDV and CPV. Nonetheless, given
the lack of published data, larger ﬁeld studies to investigate the
effects of ivermectin on immunological responses to inactivated
rabies vaccine may be warranted given that ivermectin is often
administered as part of rabies vaccination programmes.
None of the puppies had prevaccination antibody titres
>0.5 IU/ml that might be indicative of maternal antibody
against rabies. However, because of the uncertain vaccination
status of the dams, it was not possible to determine whether the
low prevaccinal antibody titre of 0.29 IU/ml detected in one
puppy in the Serengeti was the result of maternal antibody.
More detailed studies of the maternal antibody status and
immunological responses of puppies in these low-income set-
tings is also warranted, particularly as the development of
large-scale rabies control and elimination programmes across
Asia and Africa (Lapiz and others 2012, Putra and others 2013,
WHO 2013) is likely to result in an increasing proportion of
puppies born to vaccinated dams.
Rabies is a serious zoonosis that remains uncontrolled in dog
populations throughout much of Asia and Africa. Given the inad-
equacy of vaccination campaigns, a substantial proportion of free-
roaming dogs in affected communities are never vaccinated or vac-
cinated only once in their lifetime (Mitmoonpitak and others
1998, Lembo and others 2010). Although mortality in puppies less
than three months of age is generally high in these populations
(Brooks 1990, de Balogh and others 1993, Kitala and others 2001,
Gsell and others 2012, Morters and others 2014b), delaying vaccin-
ation until puppies are three months of age may result in these
TABLE 1: Day 0 (prevaccination) and day 30 (peak) titres of
the puppies vaccinated in Zenzele
Dog Gender
Age at
vaccination
(weeks)
Puppy
day 0
titres
(IU/ml)
Puppy
day 30
titres
(IU/ml)
Dam
day 0
titres
(IU/ml)
Dam
present
May 2006
1 f 8–10 0.06 11.3 0.06 Yes
2 m 8–10 0.06 2.0 0.06 Yes
3 f 7–8 – 45.3 0.18 Yes
4 m 6–7 – 22.6 0.06 No
5 m 6–7 – 45.3 0.06 No
6 f 7–8 – 16.0 0.06 No
7 m 5–6 – 64.0 0.06 No
8 f 4–6 – 45.3 0.06 Yes
9 f 5–7 – 32.0 0.06 Yes
10 f 5–7 – 64.0 0.06 Yes
11 m 5–7 – 5.7 0.06 Yes
12 m 4–6 – 45.3 0.18 Yes
13 f 4–6 – 90.5 0.18 Yes
14 f 5 – 22.6 0.06 Yes
15 f 5 – 8.0 0.06 Yes
16 f 5 – 5.7 0.06 Yes
17 f 10 days – 5.7 0.09 No
18 f 6–8 – 32.0 – –
19 f 10–12 – 22.6 – –
f, female; m, male
TABLE 2: Day 0 (prevaccination) and day 21 (peak) titres of
the puppies vaccinated in the Serengeti
Dog Gender
Age at
vaccination
(months)
Day 0
titres
(IU/ml)
Day 21
titres
(IU/ml)
Ivermectin
administered
1 m 3 0.17 >5.9 No
2 m 3 0.07 >5.9 Yes
3 f 2 0.29 >5.9 Yes
4 f 3 0.07 >5.9 No
5 m 3 0.07 >5.9 Yes
6 m 3 0.07 >5.9 Yes
7 f 2 0.07 >5.9 Yes
8 f 3 0.17 >5.9 Yes
f, female; m, male
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dogs never being vaccinated. On the basis of results of the present
study, and the risk of human beings contracting rabies from young
puppies (Mitmoonpitak and others 1997, Taiwo and others 1998,
WHO 1998, Widdowson and others 2002, Awoyomi and others
2007), all dogs in rabies endemic regions, including puppies less
than three months of age, should be vaccinated against rabies as
recommended by the WHO (WHO 2004, 2013). While puppy vac-
cination should therefore be included in annual rabies vaccination
campaigns, these efforts should not compromise vaccination of
juvenile and adult dogs, which have higher survival rates than
puppies and are therefore important in maintaining vaccination
coverage between campaigns (Morters and others 2014b). As
humoral immunity can wane rapidly in young dogs (Siegrist 2012)
and puppies are continually acquired by community members
throughout the year, it is recommended that all young dogs
should also be given primary and booster vaccinations whenever
veterinary services are available to dog owners.
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